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Purpose: Achromatopsia results from mutations in one of three genes: cyclic nucleotide-gated channel, alpha-3 (CNGA3);
cyclic nucleotide-gated channel, beta-3 (CNGB3); and guanine nucleotide-binding protein, alpha-transducing activity
polypeptide 2 (GNAT2). We report the responsible mutations in two United Arab Emirates families who have this
autosomal recessive disease.
Methods: Clinical examinations were performed in seven patients from three nuclear families. Molecular genetic testing
for common CNGA3 and CNGB3 mutations was undertaken using standard protocols.
Results: All patients were extremely light sensitive and had reduced visual acuity and no color perception. Fundus
examinations did not show any visible abnormalities. After further pedigree analysis, two of the families were found to
be linked through the paternal line. Two mutations in CNGA3 were identified: Arg283Trp and Gly397Val. Family A, the
larger pedigree, had one branch in which two sisters and one brother were homozygous for the Gly397Val mutation and
another branch in which a brother and sister were compound heterozygous for both aforenamed mutations. Family B,
however, only had two brothers who were homozygous for the Arg283Trp mutation.
Conclusions:  Achromatopsia  in  these  two  United  Arab  Emirates  families  results  from  two  different  mutations  in
CNGA3. Two branches of the same pedigree had individuals with both homozygous and compound heterozygous disease,
demonstrating a complex molecular pathology in this large family.
Achromatopsia (OMIM #216900, #26230), also known
as rod monochromacy or total color blindness, is an autosomal
recessive  congenital  cone  dystrophy  with  an  estimated
incidence of less than 1 in 30,000. [1,2] The disorder presents
in infancy with poor visual acuity, pendular nystagmus, severe
sensitivity to light, and a complete lack of color perception.
While visual acuity remains stable around 20/200 or less,
nystagmus and photophobia may decrease with age. Fundus
examination is usually normal with rare nonspecific macular
or  peripheral  changes.  The  objective  diagnosis  of
achromatopsia is based on electroretinography (ERG), which
reveals  preserved  rod  function  and  undetectable  cone
response [3].
Achromatopsia results from the absence of functional
cones  in  the  retina.  Over  the  past  decade  there  has  been
significant progress in unraveling the molecular genetics of
this rare disorder. To date, achromatopsia has been associated
with mutations in three genes that play essential roles in the
cone  phototransduction  pathway.  The  first  two  genes
discovered  were  CNGA3  and  CNGB3,  which  respectively
encode the α- and β-subunits of the cGMP-gated channel
present in cone photoreceptors [4,5]. In two large studies,
pathogenic mutations found in CNGB3 (ACHM3 locus on
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chromosome  8q21)  were  mostly  nonsense  or  frameshift
mutations and accounted for 40%–50% of cases [6,7]. In
contrast, the majority of pathogenic mutations reported in
CNGA3 (ACHM2 locus on chromosome 2q11) have mostly
been of the missense type. CNGA3 mutations are expected to
account for about 20%–30% of achromatopsia cases [8,9].
More recently, a third gene, GNAT2, was implicated in
achromatopsia  and  was  mapped  to  locus  ACHM4  on
chromosome 1p13. This gene codes for the α-subunit of the
cone  photoreceptor  transducin  G-protein  in  the
phototransduction  pathway.  Pathogenic  mutations  in
GNAT2 have been associated with only 2%–3% of cases in
studies to date [10-12].
To our knowledge, the genetic basis of achromatopsia in
United Arab Emirates has not been reported previously. We
describe here the responsible mutations in two UAE families
with this rare disorder.
METHODS
Patients  and  ophthalmologic  examination:  Seven
achromatopsia  patients  from  three  nuclear  families  were
involved in this study : the patients were recruited from the
Cleveland  Clinic  Consultation  Eye  Service  in  AbuDhabi,
United Arab Emirates. There were 3 females and 4 males
ranging in age from 5 to 16 years. Venous blood samples were
collected from all seven patients after informed consent was
obtained. IRB approval for the study was obtained from the
Cleveland Clinic Foundation and the United Arab Emirates
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1293health  authorities.  Patients  were  clinically  examined  and
followed-up  in  Abu  Dhabi,  UAE.  Ophthalmologic
examination included the assessment of best-corrected visual
acuity,  external  examination,  slit-lamp  and  funduscopic
examination, and Ishihara color vision testing. Diagnosis was
based on the presence of nystagmus, severe photophobia,
complete lack of color discrimination, and a visual acuity of
20/100 or less. ERG was not available. In one of the younger
patients, visual acuity and color vision was difficult to assess;
however clinical signs and symptoms were consistent with a
diagnosis of achromatopsia.
Molecular genetic analysis: Genetic analysis was performed
at the Molecular Genetic Laboratory of the University Eye
Hospital,  Tuebingen,  Germany.  DNA  was  extracted  from
venous blood samples approximately one week after the blood
draw. In the intervening time the samples were refrigerated.
The  most  common  prevalent  mutations  in  CNGB3  were
excluded by PCR/RFLP and PCR/denaturating high pressure
liquid chromatography (dHPLC) analysis in the index patient
from each family, as described previously [6]. All coding
exons  and  flanking  intronic  sequences  of  CNGA3  were
amplified from genomic DNA by means of PCR [4]. PCR
fragments  were  treated  with  ExoSAP  (GE  Healthcare,
Freiburg, Germany) and subjected to direct DNA sequencing
applying  BigDye  Terminator  1.1  chemistry  (Applied
Biosystems, Darmstadt, Germany). All sequences were run
on an ABI 3100 DNA sequencer, and analyzed with Sequence
Analysis  5.1  (Applied  Biosystems)  and  SeqMan  software
(Lasergene,  Madison  WI).  Segregation  analysis  was
performed for all available patients within the families by
direct sequencing of the relevant gene segment of exon 7 of
the CNGA3 gene [6].
RESULTS
Clinical findings: All patients were extremely light sensitive
and  had  reduced  visual  acuity  and  no  color  perception.
Pendular nystagmus was observed in all patients. Funduscopic
TABLE 1. CHARACTERISTICS OF THE SEVEN ACHROMATOPSIA PATIENTS EXAMINED IN THIS STUDY
Family  Patient Age Gender Visual acuity Gene Allele 1 Allele 2
A IV:1 16 Female 0.2/0.2 CNGA3 Arg283Trp Gly397Val
A IV:2 14 Male 0.2/0.2 CNGA3 Arg283Trp Gly397Val
A III:6 10 Female 0.2/0.2 CNGA3 Gly397Val Gly397Val
A III:7 8 Male 0.25/0.25 CNGA3 Gly397Val Gly397Val
A III:8 5 Female 0.2/0.2 CNGA3 Gly397Val Gly397Val
B III:1 12 Male 0.05/0.05 CNGA3 Arg283Trp Arg283Trp
B III:3 6 Male * CNGA3 Arg283Trp Arg283Trp
The asterisk indicates that the family member was not examined. A diagnosis of achromatopsia was given based on poor visual
acuity with normal fundi, photophobia, nystagmus, and lack of color vision yet the presence and independent inheritance of two
mutant CNGA3 alleles could not be confirmed unequivocally in either of the pedigrees as only affected patients and no parents
were available for segregation analysis.
Figure  1.  Pedigrees  of  family  A  and
family  B  with  autosomal  recessive
achromatopsia  originating  from  the
United  Arab  Emirates  and  carrying
mutations in the CNGA3 gene. Family
A has two branches carrying either the
two  heterozygous  mutations  R283W
and G397V or being homozygous for
the  mutation  G397V  due  to
consanguinity of the parents. Patients of
family B are both homozygous for the
mutation R283W in the CNGA3 gene.
Squares  indicate  males  and  circles
females. Open symbols indicate healthy
individuals,  while  shadings  designate
the affected patients. Arrows point to
family  members  for  whom  DNA
samples  were  available  for  genetic
analysis. CNGA3 genotypes are given
below each analyzed individual.
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1294examinations did not reveal any visible abnormalities. Patient
characteristics and findings are summarized in Table 1. After
further investigation of the pedigrees, it was found that two of
the nuclear families were linked through the paternal line in
one, shown in Figure 1A as Family A. Five children in Family
A were diagnosed with achromatopsia. Family B (Figure 1B)
is an independent family in which two children were affected.
Molecular genetic findings: We were able to identify either
homozygous  or  two  heterozygous  mutations  in  all  seven
patients from the two families, concordant with an autosomal
recessive mode of inheritance (see Table 1). The two causative
mutations,  c.847C>T  p.Arg283Trp  and  c.1190G>T
p.Gly397Val  (Figure  2),  were  both  found  in  CNGA3
(GenBank  NM_001079878).  In  Family  A,  the  pedigree
consisted of one branch in which two sisters and one brother
were homozygous for the Gly397Val mutation, and another
branch in which a brother and his sister were both compound
heterozygous for Gly397Val and Arg283Trp. In Family B,
two brothers were homozygous for the Arg283Trp mutation.
The mutation Arg283Trp is a missense mutation and has
already  been  reported  in  the  literature  [4,8,13,14].  The
mutation Gly397Val is to date unique to the patients of Family
A and has not been previously reported. It is a missense
mutation substituting a highly conserved amino acid residue
in transmembrane domain S6 of the α-subunit of the cone
cyclic-GMP gated channel.
DISCUSSION
Achromatopsia-associated  genetic  mutations  have  been
studied  in  centers  around  the  world,  though  mainly  in
Northern  European  countries  and  in  Japan.  Mutations  in
CNGA3, CNGB3, and GNAT2 have been associated with the
majority  of  studied  cases  of  achromatopsia.  To  date,  the
distribution  of  genetic  mutations  in  UAE  or  other  Arab
achromatopsia patients has not been assessed.
We have identified pathogenic mutations in CNGA3 in
two independent UAE achromatopsia families. As is true for
the majority of known CNGA3 mutations, the two mutations
we identified are missense mutations. Of the two mutations,
Gly397Val  has  not  been  reported  previously  and  may  be
unique to UAE patients. We identified this mutation in a
family with a complex pedigree in which one branch had three
individuals  who  were  homozygous  for  the  Gly397Val
mutation, and the other branch had two individuals who were
compound  heterozygous  for  Gly397Val  and  a  second
CNGA3 mutation, Arg283Trp.
The Arg283Trp mutation, which was also identified in
two  homozygous  individuals  in  the  second  family  of  our
study, has been previously reported in patients from other
parts of the world. Wissinger et al., [8] in a multinational study
of 58 independent patients with CNGA3 mutations, found the
most prevalent mutation was Arg283Trp. Together with three
other  recurrent  CNGA3  mutant  alleles,  this  mutation
accounted for nearly 42% of the total identified mutant alleles
in this large study. Even though there is a high occurrence of
Arg283Trp  in  two  different  geographic  locations—in
northern Europe and in northern Italy—further segregation
analysis  and  haplotype  reconstruction  of  the  Arg283Trp
segregating alleles in the study suggested that all observed
Arg283Trp  chromosomes  share  a  common  origin.
Independent studies of Hungarian and Swedish patients have
also reported the Arg283Trp mutation [13,14] (The Swedish
patients are included in the Wissinger study [8].). To date,
however, the Arg283Trp mutation has not been reported in
Japanese patients or in patients in the United Kingdom [7,9,
15]. Though our study is of a much smaller scale than these
studies,  it  is  notable  that  the  Arg283Trp  mutation  was
independently present in both UAE families.
We  noted  that  subject  III:6  from  Family  B,  who  is
homozygous for the aforementioned Arg283Trp mutation,
appears to also have the worst visual acuity compared to the
other subjects. The severity of the disease in this patient is
within the spectrum expected in this disorder, but yet worse
than others in his age group and ethnic background. There
have been functional analyses in our laboratory and by other
groups on this mutation by heterologous in vitro expression
of  mutant  CNGA3  channels  carrying  this  mutation  in
HEK293 cells. It was shown to be nonfunctional (functional
Figure 2. Identification of the novel CNGA3 mutation c.1190G>T
Gly397Val in Family A. Electropherogram sections of exon 7 of
CNGA3. Selected heterozygous or homozygous mutant sequences
(middle and bottom rows) compared with the respective wild-type
sequence (top row). Dotted framed encloses the nucleotide altered
by the mutation.
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1295null  mutation),  being  compatible  with  a  phenotype  of
complete achromatopsia [16].
In the multinational study by Wissinger et al., [8] it was
estimated that CNGA3 mutations were associated with only
about 25% of achromatopsia cases. A more recent study in
United  Kingdom  achromatopsia  families  showed  that
CNGA3  mutations  accounted  for  up  to  40%  of  the
achromatopsia cases in the 22 families studied [9]. In contrast,
our study showed that the cases of achromatopsia in the two
UAE families we examined were associated with CNGA3
mutations.  The  frequency  of  CNGA3  mutations  in  UAE
achromatopsia patients in this relatively small population (less
than 1 million) remains to be determined.
For  several  decades  now,  the  estimated  worldwide
prevalence of achromatopsia is quoted as 1 in 30,000. [1,2]
Certain  isolated  populations  with  a  considerably  higher
incidence than this figure have, however, been discovered and
studied extensively. For example, the disease incidence in the
Pingelapese islanders of Micronesia was reported as 1:20 with
a prevalence of a single specific CNGB3 founder mutation due
to gene drift and inbreeding [17-19]. More recently, Rojas et
al. [20,21] reported that the incidence of achromatopsia in a
rural isolate in central Chile is 1:60 and is associated with
unique  CNGB3  mutations.  The  present  study  is  not  an
epidemiologic study and does not allow the determination of
the contribution of achromatopsia to the burden of childhood
blindness in this country. However, there is a high rate of
consanguinity  in  the  UAE  and  according  to  a  1997
demographic study, the rate has increased from 39% to 50.5%
in one generation. This may consequently play a large role in
the high frequencies of recessive genetic disorders in this
population [22-24]. Furthermore, UAE nuclear families are
generally large with several children in any particular case;
we have often dealt with families with up to 12 children [25].
Population-wide  screening  for  CNGA3  mutations,  in
addition  to  genetic  counseling  in  UAE  families  and
subpopulations  affected  by  achromatopsia,  could  be
undertaken to determine carrier status and to provide informed
risk for individual families.
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